Improvement of lipid profile in Type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I

• Published in: Diabetologia Vol. 36; no. 5; pp. 465 - 469
• Main Authors: ZENOBI, P. D, HOLZMANN, P, GLATZ, Y, RIESEN, W. F, FROESCH, E. R
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01-05-1993
• Subjects: Adult; Apolipoproteins - analysis; Biological and medical sciences; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Diabetes Mellitus, Type 2 - blood; Diabetes. Impaired glucose tolerance; Eating; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Fatty Acids, Nonesterified - blood; Female; Glycated Hemoglobin A - analysis; Humans; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Insulin-Like Growth Factor I - pharmacology; Insulin-Like Growth Factor I - therapeutic use; Lipids - blood; Lipoproteins - blood; Male; Medical sciences; Middle Aged; Recombinant Proteins - pharmacology; Recombinant Proteins - therapeutic use; Time Factors; Triglycerides - blood; Endocrinopathy; Human; Somatomedin C; Risk factor; Cardiovascular disease; Lipids; Triglyceride; Non insulin dependent diabetes; Cholesterol; Growth factor
• ISSN: 0012-186X; 1432-0428
• DOI: 10.1007/BF00402285

Type 2 (non-insulin-dependent) diabetes mellitus is associated with increased glucose, insulin, total and VLDL-triglyceride, and often total and LDL-cholesterol levels which promote vascular disease. Recombinant human insulin-like growth factor-I which mimics many effects of insulin, decreased insulin, total and VLDL-triglyceride, and total and LDL-cholesterol levels in healthy man as well as glucose and insulin levels in Type 2 diabetic patients. We, therefore, investigated total and fractionated triglyceride and cholesterol levels, lipoprotein(a), non-esterified fatty acid, and apolipoprotein levels in eight Type 2 diabetic patients during five control, five treatment, and three wash-out days. They received a constant diet throughout and daily 2 x 120 micrograms insulin-like growth factor-I/kg s.c. during the treatment period. Fasting total and VLDL-triglyceride, total and LDL-cholesterol control levels were (mean +/- SD) 3.1 +/- 2.6, 1.3 +/- 1.0, 6.3 +/- 1.3, and 4.5 +/- 1.1 mmol/l and decreased to 1.6 +/- 0.8, 0.6 +/- 0.4, 5.0 +/- 1.0, and 3.5 +/- 1.1 mmol/l, respectively, on the last treatment day (p < 0.01). During therapy, fasting lipoprotein(a) levels and the postprandial area under the triglyceride curve decreased by 48 +/- 22 and 32 +/- 18% of control (p < 0.01), respectively. In conclusion, insulin-like growth factor-I lowered lipid levels in Type 2 diabetic patients directly or indirectly or both because of decreased glucose and insulin levels. Long-term trials would be of interest with respect to the cardiovascular risk in Type 2 diabetes and patients with hyperlipidaemia.